|
Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. |
|
|
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen |
Research Funding - ARIAD (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Pfizer (Inst) |
|
|
|
Stock and Other Ownership Interests - Genentech |
Patents, Royalties, Other Intellectual Property - Genentech |
|
|
|
|
|
Consulting or Advisory Role - GE Healthcare; Genecentric; Genentech/Roche; GlaxoSmithKline; Lilly |
Speakers' Bureau - Boehringer Ingelheim; Pfizer |
Research Funding - Bayer; Genentech; Merck; Myriad Genetics; OncoPlex Diagnostics |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Roche Pharma AG |
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Roche Pharma AG |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Biothera; Bristol-Myers Squibb; Genentech (Inst); Lilly; Novartis; Pfizer; Synta |
Research Funding - Amgen; Celgene; Genentech; ImClone Systems |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
Honoraria - Boehringer Ingelheim; Genentech/Roche; GlaxoSmithKline; Johnson & Johnson; Lilly; Pfizer |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Genentech/Roche; GlaxoSmithKline; Johnson & Johnson; Lilly; Pfizer |
Speakers' Bureau - Genentech/Roche; Lilly; Pfizer |
Research Funding - ArQule |
|
|
|
|
|
|
|
|
No Relationships to Disclose |